Monoclonal Antibodies as Neurological Therapeutics.

Pharmaceuticals (Basel) · 2021 · PMC7912592 · PMID 33530460

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

In a phase II clinical trial, in patients with optic neuritis failed to reach significance in recovery of latency in visual evoked potentials, using the contralateral eye as a baseline, compared to placebo [ 134 ].

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.